Biotia will present its industry-changing technology that enables more accurate detection of pathogens in urine samples compared to traditional methods.

NEW YORK, Oct. 18, 2022 /PRNewswire-PRWeb/ — Biotia, Inc., a health-tech company fighting infectious disease through the power of genomics and artificial intelligence, announced today that it will be presenting at IDWeek 2022. The presentation, titled “Clinical-Grade Metagenomics in Urinary Tract Infections: Improving Performance of Next-Generation Sequencing Assays Using Internal Controls and Machine Learning,” will be delivered on October 20, from 12:15 to 1:30 p.m.

Urinary tract infections are among the most common outpatient infections in the United States, leading to 7 million doctor visits annually. However, gold-standard technologies, like existing culture technology, do not yield definitive diagnostic results in one-third of patients. This percentage is even higher in immunocompromised patients — such as cancer or transplant patients — for whom infectious disease is the second leading cause of death.

Recognizing this need, Biotia leverages next-generation sequencing (NGS) to generate genomic data. The company utilizes an advanced computational AI platform and an integrated software, data and lab toolkit to provide accurate characterization of microbial species, antimicrobial resistance and virulence factors, improving diagnostics for infectious diseases.

“Our NGS urine assay by leveraging machine learning software and internal positive control provides greater sensitivity and taxonomic specificity,” said Dr. Dorottya Nagy-Szakal, chief medical officer at Biotia. “With it, we open the door to better guide patient care and improve mortality rates in immunocompromised patients, those for whom conventional diagnostics frequently fail and who have a higher risk of developing sepsis.”

IDWeek is an industry-leading conference that brings together over 10,000 healthcare professionals working in the field of infectious disease, including researchers, clinicians, public health officials and quality and patient safety practitioners.

“We are delighted that we were selected to present our clinical validation data and clinical-grade metagenomics tool that enables more accurate detection of pathogens in urine samples compared to culture,” said Mara Couto-Rodriguez, director of research and development at Biotia. “We have focused on bringing stringent standards to the field of metagenomics to decrease the number of false positives calls and provide meaningful insights.”

For more information, contact info@biotia.io.

About Biotia
Biotia is a health-tech company located in New York, NY, that leverages sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Their mission is to fight infectious diseases by deploying the leading reference library of microbes worldwide. As a spinout company of Jacobs Technion-Cornell Institute at Cornell Tech, Biotia has a New York State CLIA lab for infectious disease diagnostics testing affiliated with SUNY Downstate Health Sciences University.

Connect on Twitter, Facebook and LinkedIn.

Media Contact

Lathum Nelson, Stage Marketing, (385) 743-1724, lathum.nelson@stagemarketing.com

SOURCE Biotia